Tirzepatide
FDA label for a specific indication
FDA-approved drug — specific formulations and indications
FDA-approved formulations have specific indications; compounded products are not FDA approved. Source: FDA: concerns with unapproved GLP-1 drugs
What it is
A GIP and GLP-1 receptor agonist. Source: Tirzepatide injection — FDA prescribing information, sections 2.1–2.2, 4, 5 and 12.1 (DailyMed)
What it has been studied for
Weight reduction in the labeled population, alongside diet and physical activity. Source: Tirzepatide injection — FDA prescribing information, sections 2.1–2.2, 4, 5 and 12.1 (DailyMed)
Mechanism
Acts on GIP and GLP-1 receptors involved in appetite and glucose regulation. Source: Tirzepatide injection — FDA prescribing information, sections 2.1–2.2, 4, 5 and 12.1 (DailyMed)
Documented dosing
Dr. Axe’s educational micro-dose approach
Daily protein target: Not set. Cellular Bloodwork Analysis →
Protect muscle: Include regular resistance training suited to your ability, alongside adequate protein, to help protect muscle while weight comes off. Clinical advisory
Dr. Axe’s educational position is to explore 10–20% of the standard labeled dose. This is arithmetic, not an FDA-labeled regimen or a proven equivalent treatment. This tool does not tell you to cut or change your prescription.
Standard dose means the labeled dose for the selected drug and titration step. Adult weight reduction · subcutaneous injection · once weekly. FDA prescribing information
Standard dose: 2.5 mg. First 4 weeks · starting dose, not maintenance.
10–20%: 0.25–0.5 mg
Confirm your vial concentration in the calculator to see mL and syringe units.
These conversions use the concentration you entered. They are not instructions to dilute a ready-to-use medicine or withdraw medicine from a pen.
Pairings & cautions
No evidence-based peptide pairing is specified in this entry.
The label includes a thyroid C-cell tumor boxed warning and contraindications involving medullary thyroid cancer or MEN2. Gastrointestinal effects and pancreatitis are among the precautions. Source: Tirzepatide injection — FDA prescribing information, sections 2.1–2.2, 4, 5 and 12.1 (DailyMed)
These are selected considerations, not a complete safety review. Discuss the full source and your medications with your prescriber.
Sources
- Tirzepatide injection — FDA prescribing information, sections 2.1–2.2, 4, 5 and 12.1 (DailyMed) · FDA label
- FDA: concerns with unapproved GLP-1 drugs · Clinical / regulatory reference